You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
McKesson
Merck
Boehringer Ingelheim

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HALOPERIDOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Haloperidol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000274 Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Completed New York State Psychiatric Institute Phase 2 1997-03-01 The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000274 Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-03-01 The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00006195 Glucose Regulation During Risperidone and Olanzapine Treatment Unknown status Janssen, LP N/A 1969-12-31 The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin. Undesirable changes in blood sugar control, or glucose regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia compared to healthy subjects and subjects with other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia before the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Attention to the way that antipsychotic medications may affect glucose regulation has increased as doctors have become more concerned in general about disease- and drug-related medical complications, including weight gain during antipsychotic treatment.
NCT00006195 Glucose Regulation During Risperidone and Olanzapine Treatment Unknown status Washington University School of Medicine N/A 1969-12-31 The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin. Undesirable changes in blood sugar control, or glucose regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia compared to healthy subjects and subjects with other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia before the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Attention to the way that antipsychotic medications may affect glucose regulation has increased as doctors have become more concerned in general about disease- and drug-related medical complications, including weight gain during antipsychotic treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Haloperidol

Condition Name

Condition Name for Haloperidol
Intervention Trials
Schizophrenia 63
Delirium 32
Schizoaffective Disorder 13
Agitation 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Haloperidol
Intervention Trials
Schizophrenia 69
Delirium 45
Psychotic Disorders 29
Psychomotor Agitation 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Haloperidol

Trials by Country

Trials by Country for Haloperidol
Location Trials
United States 181
Netherlands 17
China 16
Spain 15
Brazil 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Haloperidol
Location Trials
Texas 17
New York 16
California 12
Pennsylvania 11
Missouri 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Haloperidol

Clinical Trial Phase

Clinical Trial Phase for Haloperidol
Clinical Trial Phase Trials
Phase 4 71
Phase 3 38
Phase 2/Phase 3 7
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Haloperidol
Clinical Trial Phase Trials
Completed 104
Recruiting 27
Terminated 19
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Haloperidol

Sponsor Name

Sponsor Name for Haloperidol
Sponsor Trials
Janssen, LP 6
National Institute of Mental Health (NIMH) 6
Washington University School of Medicine 5
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Haloperidol
Sponsor Trials
Other 262
Industry 52
NIH 20
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Baxter
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.